Acute Myeloid Leukemia Clinical Trial

A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Summary

This study is being done to evaluate the safety, tolerability and antitumor activity of oral CG-806 (luxeptinib) for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary AML, therapy-related AML, or higher-risk MDS, whose disease has relapsed, is refractory or who are ineligible for or intolerant of intensive chemotherapy or transplantation.

View Full Description

Full Description

This is a multicenter, open-label, Phase 1 a/b dose escalation study of safety, pharmacodynamics, and pharmacokinetics of CG-806 in ascending cohorts (3+3 design) to determine the MTD or recommended dose in patients with relapsed or refractory Acute Myeloid Leukemia (except APML), secondary AML, therapy-related AML, or higher-risk MDS whose disease has relapsed, is refractory or who are ineligible for or intolerant of intensive chemotherapy or transplantation. This is to be followed by a cohort expansion phase.

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Age ≥18 years
Life expectancy of at least 3 months
ECOG Performance Status ≤ 2
Patients must be able to swallow capsules
Adequate hematologic parameters, unless cytopenias are disease caused
Adequate renal, liver and cardiac functions

Key Exclusion Criteria:

Patients with GVHD requiring systemic immunosuppressive therapy
Uncontrolled leptomeningeal disease, auto-immune hemolytic anemia and uncontrolled and clinically significant disease related metabolic disorder
Clinically significant leukostasis
Treatment with other investigational drugs or receipt of cytotoxic therapy within 14 days prior to first study treatment administration
Receipt of cellular immunotherapeutic agents within 4 weeks prior to first study treatment administration

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

80

Study ID:

NCT04477291

Recruitment Status:

Recruiting

Sponsor:

Aptose Biosciences Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 11 Locations for this study

See Locations Near You

City of Hope National Medical Center
Duarte California, 91010, United States More Info
Rochelle Hernandez
Contact
626-218-0247
[email protected]
Paul Koller, MD
Principal Investigator
St Joseph Heritage Healthcare
Fullerton California, 92835, United States
University of Southern California
Los Angeles California, 90033, United States More Info
Christine Duran
Contact
[email protected]
Eric L Tam, MD
Principal Investigator
University of Miami
Miami Florida, 33136, United States More Info
Jennifer Posada
Contact
[email protected]
Namrata Chandhok, MD
Principal Investigator
Northwestern University
Chicago Illinois, 60611, United States More Info
Sophia Rollyson
Contact
312-695-8128
[email protected]
Jessica Altman, MD
Principal Investigator
Ochsner Healthcare
New Orleans Louisiana, 70121, United States More Info
Natalie Santos
Contact
504-703-2652
[email protected]
Michelle Schmidt
Contact
504-842-6097
[email protected]
Laura Finn, MD
Principal Investigator
Atlantic Hematological Oncology Center
Morristown New Jersey, 07962, United States More Info
Salome Geene
Contact
973-971-6373
[email protected]
Amanda Hall
Contact
973-971-5235
[email protected]
Mohamad Cherry, MD
Principal Investigator
Roswell Park Comprehensive Cancer Center
Buffalo New York, 14263, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States More Info
Naa-Akomaah Yeboah
Contact
[email protected]
Michelle Gianvito
Contact
[email protected]
Aaron Goldberg, MD
Principal Investigator
University Hospital of Cleveland
Cleveland Ohio, 44106, United States More Info
Sarah Golwitzer
Contact
216-286-0112
[email protected]
Susan Ackerman
Contact
216-286-4150
[email protected]
Benjamin Tomlinson, MD
Principal Investigator
University of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States More Info
Julio Guerrero
Contact
713-745-6771
[email protected]
Maro Ohanian, DO
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

80

Study ID:

NCT04477291

Recruitment Status:

Recruiting

Sponsor:


Aptose Biosciences Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.